Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Taishi Yamashita, Hidemi Takahashi, Koji Tamada, Kiyoyuki Ogata, Kazuo Dan, Eiji Shinya, Hideto Tamura, Lieping Chen, Wanhong Zhao, Asaka Kondo, Takashi Tsuji, Masumi Shimizu
Publikováno v:
Blood. 116:1124-1131
During disease progression in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells become less efficient via an unknown mechanism. Using MDS cell lines and patient samples, we showed that the ex
Autor:
Wolfram Jung, Peter Staib, Heike Tinnefeld, Paul Scigalla, R. Kuse, Joerg Thomalla, Hubert Serve, Walter Fiedler, Mark Jacobs, Wolfgang E. Berdel, Anne Marie O'Farrell, Oliver G. Ottmann, Ulrich Dührsen, Michael Flasshove, Sonja Loges, Nicoletta Brega, Franco Cavalli, Dieter K. Hossfeld, Rolf M. Mesters
Publikováno v:
Blood. 102:2763-2767
Neoangiogenesis has been shown to play an important role in the pathogenesis of acute myeloid leukemia (AML). Autocrine and paracrine secretion of angiogenic and hematopoietic growth factors such as vascular endothelial growth factor (VEGF) and stem
Autor:
Adrian Wiestner, Rashida Z. Mustafa, Jennifer Gyamfi, Sarah E. M. Herman, Mohammed Farooqui, Betty Chang, Stefania Pittaluga, Stella Chang
Publikováno v:
Blood. 123(21)
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, tissue-resident CLL cells show prominent activation of both B-cell receptor (BCR) and NF-κB pathways. We evaluated the in vi
Autor:
Pellegrino Musto, Luciana Teofili, Luigi Maria Larocca, Anna Laura Di Febo, Sergio Rutella, Nicola Di Renzo, Giuseppe Leone, Antonella Cingolani, Nicola Maggiano, Stefano Pileri, Maurizio Bendandi, Francesco Pierconti
Publikováno v:
Blood. 97:1063-1069
The receptor for hepatocyte growth factor (HGF) is a transmembrane tyrosine kinase that is encoded by the proto-oncogene c-met. Recently, c-MET was detected in Reed-Sternberg (RS) cells from Epstein-Barr virus–positive (EBV+) Hodgkin disease (HD).
Autor:
James D. Griffin, Edward A. Fox, Jennifer J. Clark, Pamela S. Cohen, David Lebwohl, Stephen D. Nimer, Richard Stone, D. Gary Gilliland, Wilson Grandin, Virginia M. Klimek, Yanfeng Wang, Daniel J. DeAngelo, Donna Neuberg, Ilene Galinsky, Eli Estey
Publikováno v:
Blood. 105(1)
Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refracto
Autor:
Wolfgang E. Berdel, Berno Dankbar, Birgit Feldmann, Hubert Serve, Rolf M. Mesters, R. Leo, Martin Kropff, Joachim Kienast, Teresa Padró
Publikováno v:
Europe PubMed Central
Vascular endothelial growth factor (VEGF), a multifunctional cytokine, potently stimulates angiogenesis including tumor neovascularization. Although well established in solid tumors, the role of VEGF in bone marrow neoangiogenesis and paracrine tumor
Publikováno v:
Blood. 90(2)
Acute promyelocytic leukemia (APL) is a neoplasm with the unique chromosomal translocation t(15; 17), which involves the retinoic acid receptor α gene. All-trans retinoic acid (ATRA) has been used for APL patients as a potent therapeutic agent to in
Publikováno v:
Blood. 67:1154-1161
To determine the effects of the “maturation-inducing” agents 13-cis retinoic acid and 1,25 dihydroxyvitamin D3 on marrow cells from normal individuals and patients with myelodysplastic syndromes (MDS), we assessed marrow hemopoietic clonogenicity